CEPI will provide up to $33 million to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the prefusion form of the spike protein from the B.1.351 strain first identified in South Africa, through phase I clinical development.

Additionally, the funding will support preclinical expansion of additional multivalent vaccine candidates designed to evaluate the potential breadth of VBI's eVLP technology. This preclinical expansion aims to develop clinic-ready vaccine candidates that can address emerging variants.

FDA accepts VBI's hepatitis B vaccine BLA
The U.S. Food and Drug Administration (FDA) has accepted the biologics license application (BLA) submitted by VBI Vaccines for its 3-antigen prophylactic...

VBI provides COVID-19 vaccine updates amid supply chain delays
VBI Vaccines has provided preclinical updates on its two COVID-19 vaccine programs: VBI-2901, a trivalent pan-coronavirus vaccine candidate, and VBI-2902,...

Therapure to manufacture VBI coronavirus vaccines
Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates.

CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture...

CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.